MBX MBX Corp: Enterprise Value to EBITDA Ratio

Brandmark of MBX Bio (MBX)

MBX Biosciences Inc (MBX) relies on a strong team of peptide experts while actively recruiting specialists in US law. Despite steady demand, the business faces risks from logistical disruptions and geopolitics. This price chart on GURU.Markets illustrates valuation trends, showing an EV/EBITDA of 0.00. The financial model is based on the procurement of innovative injections by insurance companies and medical centers for the treatment of hormonal pathologies.

MBX Biosciences, Inc. - MBX EV/EBITDA Multiple (period 11/23/2025 - 11/12/2026)

MBX (mbxbio.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price MBX Bio|MBX - Average Forecast Price
- company stock capitalization data:
Market Valuation MBX Corp|MBX - Aggregate Business Value
- business book valuation details:
Book Value per Share MBX Biosciences|MBX - Book Capitalization|Market Capitalization to Book Value Ratio mbxbio.com|MBX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity MBX Biosciences Inc|MBX - Long-Term Liabilities to Capital|Short-Term Debt to Equity MBX Biosciences|MBX - Company Debts|Debts to Book Capitalization MBX Corp|MBX - Long-Term Debt Volume|Company Short-Term Debt MBX Biosciences|Quick Liquidity mbxbio.com
- financial results and valuation multiples details:
MBX - Net Income|Expected Profit MBX Biosciences Inc|MBX - Price to Earnings Ratio|Forward P/E Multiple MBX Biosciences Inc|MBX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio MBX Corp|MBX - Operating profit before amortization|Net earnings per share for the last 12 months MBX Biosciences|MBX - Earnings per share for the trailing year|Quarterly EPS earnings growth mbxbio.com|MBX - Earnings per share growth in current year|Earnings growth forecast for next year MBX Biosciences Inc
Summary company analytics:MBX Bio MBX
Original product of MBX Biosciences

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation and interest. The integration of ESG standards into the production of endocrine drugs at MBX Biosciences Inc (MBX) impacts the cost structure, which is reflected in the enterprise value to EBITDA level on the GURU.Markets platform. A decrease in this ratio may signal that assets are undervalued. It is critical for investors to distinguish a favorable entry point from a systemic decline in revenue.

Analysis of competing companies

EV/EBITDA Multiple ASND (Ascendis Pharma Inc.)|Madrigal Corp (MDGL) - Company Value to EBITDA|CORT: Enterprise Value to EBITDA Ratio|rhythmtx.com - Enterprise Value to Operating Income Before Depreciation Ratio|AKRO: EV/EBITDA Multiple|Metsera, Inc. (MTSR) - EV/EBITDA Multiple|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRNX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NewAmsterdam Pharma (NAMS)|SLNO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Agios Pharmaceuticals Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Structure Corp GPCR|MiMedx Group, Inc. (MDXG) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|Enterprise Value to EBITDA Ratio Altimmune Inc (ALT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|EV/EBITDA Multiple BIOA (BioAge Labs, Inc.)|biomeafusion.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to EBITDA Ratio|GUTS (Fractyl Health Inc.) - Enterprise Value to Operating Income Before Depreciation|VTVT (vtvtherapeutics.com) - Enterprise Value to EBITDA Ratio|Agape ATP - Business Value to Operating Income Before Depreciation|PLUR (Pluristem Therapeutics) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Total Company Value to Operating Income Before Depreciation Ratio matinasbiopharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spruce Biosciences SPRB|Galecto Corporation (GLTO) - Company Value to EBITDA|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio lumos-pharma.com LUMO|ONVO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Radius Recycling Inc.